67
1
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12010 |
Aurora B inhibitor 1
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Aurora B inhibitor 1 是一种 Aurora B (Aurora-1) 抑制剂(Ki <0.010 uM),具有潜在的抗癌活性,可用于研究癌症。 | |||
T9040 |
Aurora kinase inhibitor-2
IUN-70219,Aurora Kinase Inhibitor II |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Aurora kinase inhibitor-2 (IUN-70219) 是一种可渗透细胞的苯胺喹唑啉,可抑制极光激酶的活性,对Aurora A 和Aurora B 的IC50分别为 390 nM 和 240 nM。 | |||
T35570 |
Chiauranib
CS2164,西奥罗尼 |
c-Fms; VEGFR; FLT; PDGFR; c-Kit; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
Chiauranib 是一种针对肿瘤血管生成的多靶点抑制剂,具有强大的抗癌作用。 Chiauranib 有效抑制血管生成相关激酶(VEGFR1、VEGFR2、VEGFR3、PDGFRα 和 c-Kit)、有丝分裂相关激酶 Aurora B 和慢性炎症相关激酶 CSF1R,IC50 值范围为 1-9 nM。 | |||
T6435 |
CCT129202
2-[4-[6-氯-2-(4-二甲基氨基苯基)-3H-咪唑并[4,5-B]吡啶-7-基]哌嗪-1-基]-N-(噻唑-2-基)乙酰胺 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
CCT129202 是一种 ATP 竞争性泛极光激酶抑制剂,作用于 Aurora A、Aurora B 和 Aurora C,IC50 分别为 0.042 μM、0.198 μM 和 0.227 μM。 | |||
T6077 |
ZM-447439
|
Apoptosis; MEK; Src; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; MAPK; Tyrosine Kinase/Adaptors |
ZM 447439是一种极光激酶 (aurora) 抑制剂,对aurora A 和B 的IC50值分别为110和130 nM。 | |||
T2509 |
Tozasertib
MK-0457,VX 680 |
Aurora Kinase; Autophagy | Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Tozasertib (MK-0457) 是一种 Aurora A/B/C 激酶抑制剂,Ki 值分别为 0.6、18和4.6 nM。它显示出对 190 多种不同激酶的选择性。 | |||
T2602 |
Barasertib-HQPA
1H-Pyrazole-3-acetamide,Barasertib,AZD1152-HQPA,AZD2811,AZD1152-HQPA|AZD2811 |
Apoptosis; Aurora Kinase | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Barasertib-HQPA (AZD2811) 是一种高度选择性的极光激酶B 抑制剂,在非细胞试验中IC50值为0.37 nM。它可阻滞癌细胞生长,诱导凋亡。 | |||
T2611 |
CCT 137690
CCT137690 |
Apoptosis; Aurora Kinase | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
CCT 137690是一种有口服活性的极光激酶抑制剂,对极光激酶A、B 和C 的IC50值分别为15、25 和19 nM。 | |||
T6338 |
PHA-680632
PHA 680632,PHA680632 |
FGFR; PLK; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
PHA-680632 是一种极光激酶抑制剂,对极光激酶 A、B 和C 的IC50值分别为 27、135和 120 nM。它对 FGFR1、FLT3、LCK、PLK1、STLK2 和 VEGFR2/3 的 IC50 高 10 到 200 倍。 | |||
T1825 |
Reversine
|
Aurora Kinase; Adenosine Receptor; Autophagy | Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic; GPCR/G Protein; Neuroscience |
Reversine 是一种 ATP-竞争性 Aurora kinase 抑制剂,作用于Aurora A、Aurora B 和Aurora C,IC50分别为 400、500 和 400 nM。 | |||
T6380 |
AMG 900
AMG900,AMG-900,莪术醇.姜黄醇 |
p38 MAPK; Tyrosine Kinases; Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic; MAPK; Tyrosine Kinase/Adaptors |
AMG 900 是一种有效且高度选择性的泛极光激酶抑制剂,对Aurora A、B 和C 的IC50分别为 5 nM、4 nM 和 1 nM。 | |||
TQ0059 |
Ilorasertib
ABT-348 |
VEGFR; FLT; c-RET; PDGFR; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
Ilorasertib (ABT-348) 是一种 ATP 竞争性多靶点激酶抑制剂,可抑制 Aurora A、Aurora B 和Aurora C,IC50值为120 nM、7 nM 和1 nM。它还抑制 RET 酪氨酸激酶、PDGFRβ 和 Flt1,IC50为7 nM、3 nM 和 32 nM。 | |||
T8685 |
SP-146
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SP-146 是一种选择性、有效且非 ATP 竞争性的 Aurora B 抑制剂(IC50:0.316 nM)。 | |||
T6129 |
GSK-1070916
GSK-1070916A,GSK1070916 |
Apoptosis; Tie-2; FLT; AMPK; Aurora Kinase | Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
GSK-1070916 (GSK-1070916A) 是一种选择性,ATP 竞争型的极光激酶B/C 抑制剂,Ki 值分别为0.38和1.5 nM。 | |||
T34787 |
TAS-119
TAS119,TAS2104,TAS 2104,TAS-2104,TAS 119 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
TAS-119 (TAS-2104) 是一种可口服且具有选择性和有效性的 Aurora A 抑制剂,IC50为1.0 nM。TAS-119 对 Aurora B 也具有抑制作用,IC50 为 95 nM。TAS-119 对 Aurora A 的亲和力比 Aurora B高。TAS-119 具有有效的抗肿瘤活性和潜在的抗有丝分裂活性。 | |||
T6532 |
Hesperadin
|
Influenza Virus; Parasite; Aurora Kinase; Autophagy | Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Microbiology/Virology |
Hesperadin 是 Aurora A 和 B 的 ATP 竞争性吲哚酮抑制剂,抑制 Aurora B 的 IC50值为250nM。它通过阻断核分裂和胞质分裂而抑制布鲁氏锥虫的生长。它也是一种广谱流感抗病毒剂。 | |||
T11638 |
Ilorasertib hydrochloride
ABT-348 hydrochloride |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Ilorasertib hydrochloride (ABT-348 hydrochloride) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora C, Aurora B, and Aurora A (IC50s: 1 nM, 7 nM, 120 nM). It also suppresses RET tyrosine kinase, PDGFRβ, and Flt1 (IC50s: 7 nM, 3 nM, and 32 nM). | |||
T14371 |
Barasertib
巴拉塞替,AZD1152 |
Apoptosis; Aurora Kinase | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Barasertib (AZD1152) 是 Barasertib-hQPA 的前体药物,在癌细胞中诱导生长停滞和凋亡。它是高度选择性的Aurora B 抑制剂,IC50值为 0.37 nM。 | |||
T2617 |
SNS-314 Mesylate
SNS-314 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SNS-314 Mesylate (SNS-314) 是一种有效且特异性的极光激酶抑制剂,对极光激酶 A、B、C 的 IC50值分别为 9,31 和 3 nM。 | |||
T16359 |
NU6140
|
CDK; Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
NU6140 是选择性CDK2-cyclin A 抑制剂,IC50为0.41 μM。它显示出比其他 CDK 高 10 到 36 倍的选择性。它还抑制Aurora A 和Aurora B 的活性,IC50值分别为 67 和 35 nM。它还增强细胞凋亡作用并具有抗癌活性。 | |||
T41256 |
SP-96
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SP-96 是一种高效的特异性 Aurora B 抑制剂,IC50 为 0.316 nM。 SP-96 在 NCI60 筛选中显示特异性生长抑制,如 MDA-MD-468 (GI50=107 nM)。 SP-96 可用于三阴性乳腺癌研究。 | |||
T15815 |
LY3295668
AK-01 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
LY3295668 (AK-01) 是 Aurora A 的选择性抑制剂,对 Aurora A 和 B 的 Kis 分别为 0.8 nM 和 1038 nM。 | |||
T6126 |
JNJ-7706621
JNJ 7706621 |
Apoptosis; CDK; Aurora Kinase | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
JNJ-7706621 是一种aurora kinase 抑制剂,有效抑制CDK1和CDK2,对CDK1,CDK2,aurora-A 和aurora-B 的IC50值分别为 9 nM,3 nM,11 nM 和 15 nM。 | |||
T6458 |
CYC-116
噻氯匹定 |
VEGFR; FLT; CDK; S6 Kinase; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
CYC116是一种有效的极光激酶 A 和 B 的抑制剂,Ki 值分别为8和9 nM。 | |||
T6767 |
TCS7010
Aurora A Inhibitor I |
Apoptosis; Aurora Kinase | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
TCS7010 (Aurora A Inhibitor I) 是一种选择性的 Aurora A 抑制剂,IC50值为 3.4 nM。 | |||
T3068 |
AT9283
J-504568 |
Apoptosis; FLT; JAK; Bcr-Abl; Aurora Kinase; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors |
AT9283 (J-504568) 是一种多靶点激酶抑制剂,抑制多种实体瘤在体内外的生长和存活,有效抑制Aurora A/B,JAK2/3,Abl (T315I),和Flt3,IC50值范围为 1-30 nM。 | |||
T10215 |
AAPK-25
|
Apoptosis; PLK; Aurora Kinase | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
AAPK-25 是选择性的Aurora/PLK 激酶双重抑制剂,显示出抗肿瘤活性。它可造成有丝分裂延迟并阻滞前中期细胞,通过生物标志物组蛋白 H3Ser10磷酸化反应,导致细胞凋亡激增。 | |||
T2241 |
Alisertib
MLN 8237,4-[[9-氯-7-(2-氟-6-甲氧基苯基)-5H-嘧啶并[5,4-D][2]苯并氮杂卓-2-基]氨基]-2-甲氧基苯甲酸 |
Apoptosis; Aurora Kinase; Autophagy | Apoptosis; Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Alisertib (MLN 8237) 是一种 Aurora A 激酶抑制剂 (IC50=1.2 nM),具有口服活性和选择性。Alisertib 具有抗肿瘤活性,可以诱导细胞凋亡和自噬,诱导细胞周期阻滞。 | |||
T2094 |
Danusertib
PHA-739358 |
FGFR; Trk receptor; c-RET; Bcr-Abl; Aurora Kinase; Autophagy | Angiogenesis; Apoptosis; Autophagy; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
Danusertib (PHA-739358) 是一种极光激酶抑制剂,能够抑制 Aurora A、Aurora B 和 Aurora C 的活性,IC50值分别为 13、79 和 61 nM。它是一种具有潜在抗肿瘤活性的小分子 3-氨基吡唑衍生物。 | |||
T68405L |
KW-2450 Formate
|
Tyrosinase | Proteases/Proteasome |
KW-2450 Formate 是一种 IGF-1R/IR酪氨酸激酶抑制剂,具有抗肿瘤作用,通过抑制 Aurora A 和 B 激酶发挥作用。KW-2450 Formate 抑制 TNBC异种移植物的生长,诱导四倍体积累。 | |||
T22012 |
7BIO
|
FLT; DYRK; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Tyrosine Kinase/Adaptors |
7BIO 是靛玉红的衍生物,抑制细胞周期蛋白依赖性激酶5 和糖原合酶激酶-3β。它抑制 Aβ 寡聚体诱导的神经炎症、突触损伤、tau 过度磷酸化、星形胶质细胞和小胶质细胞的活化,并减轻 Aβ 寡聚体诱导的小鼠认知障碍。 | |||
T6039 |
TAK-285
TAK285,TAK 285 |
EGFR; MEK; HER; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Tyrosine Kinase/Adaptors |
TAK-285 是一种新型 HER2 和 EGFR(HER1) 双重抑制剂,IC50 分别为 17 和 23 nM。它可穿过血脑屏障,有抗肿瘤活性,对 HER1/2 的选择性是 HER4 的 10 倍以上。 | |||
T22288 |
(1E)-CFI-400437 dihydrochloride
CFI-400437 dihydrochloride |
PLK | Cell Cycle/Checkpoint |
(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) 是一种选择性和有效的 polo 样激酶 4 (PLK4) 抑制剂,IC50为 0.6 nM。它还抑制 Aurora A、 Aurora B、 KDR 和 FLT-3,IC50分别为 0.37、0.21、0.48 和 0.18 μM,具有抗增殖活性。 | |||
T10412 |
Aurora inhibitor 1
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase). | |||
T16862 |
SCH-1473759
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SCH-1473759 is an inhibitor of the aurora (IC50s: 4 and 13 nM for Aurora A and B, respectively). | |||
T12864 |
SCH-1473759 hydrochloride
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SCH-1473759 hydrochloride 是一种多靶点极光激酶抑制剂,对极光激酶 A 和 B 的 IC50值分别为 4 和13 nM。 | |||
T23426 |
TC-A 2317 hydrochloride
|
Others; Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Others |
TC-A 2317 hydrochloride 是 Aurora 激酶 A 的抑制剂,Ki 为 1.2 nM,而 Aurora 激酶 B 的 Ki 为 101 nM。 TC-A 2317 hydrochloride 显示出抗肿瘤活性。 | |||
T6936 |
PF-03814735
|
FAK; VEGFR; FLT; Trk receptor; Aurora Kinase | Angiogenesis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
PF-03814735 是一种新型、有效和可逆的极光激酶 A 和 B 抑制剂,IC50值分别为0.8和5 nM。 | |||
T21298 |
SNS-314
SNS-314 free base,SNS314,SNS 314 |
Others | Others |
SNS-314, a synthetic small molecule Aurora kinase (AK) inhibitor with potential antineoplastic activity, selectively binds and inhibits AKs A and B, resulting in the inhibition of cell division and proliferation in tumor cells that overexpress AKs. | |||
T63905 |
Hesperadin hydrochloride
|
Others | Others |
Hesperadin hydrochloride 是一种 Aurora A 和 B 的 ATP 竞争性吲哚酮抑制剂,对 Aurora B 的 IC50 值为 250 nM。 | |||
T8537 |
Tripolin A
(3E)-3-[(2,5-二羟基苯基)亚甲基]-1,3-二氢-2H-吲哚-2-酮 |
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
Tripolin A 是一种特异性的非 ATP 竞争性 Aurora A 激酶抑制剂,对Aurora A 和Aurora B 的IC50分别为1.5 μM 和7 μM。 | |||
T68234 |
BI-831266
|
Others | Others |
BI-831266 is a potent and selective Aurora kinase B inhibitor. | |||
T62789 |
Aurora kinase inhibitor-9
|
Others | Others |
Aurora kinase inhibitor-9 (compound 9d) 是一种有效的 AURKA/B 双极光激酶抑制剂,作用于 Aurora A (IC50: 0.093 μM)、Aurora B (IC50: 0.09 μM)。Aurora kinase inhibitor-9 具有广谱抗增殖活性。 | |||
T70401 |
HOI-07
|
Others | Others |
HOI-07 is a specific Aurora B inhibitor. | |||
T71112 |
SAR156497
|
Others | Others |
SAR156497 is an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo efficacy with IC50 = 0.5 nM (Aurora A); 1 nM (Aurora B / incenp); 3 nM (Aurora C / incenp) respectively SAR156497 combines high in vitro potency with satisfactory metabolic stability and limited CYP 3A4 and PDE3 inhibition. In vitro, SAR156497 displayed high antiproliferative activity on a large panel of tumor cell lines without correlation with any particular genetic signature or Aurora kinases expressi... | |||
T63853 |
Aurora kinase inhibitor-10
|
Others | Others |
Aurora kinase inhibitor-10 是一种口服具有活力的Aurora B 抑制剂 (IC50: 8 nM),表现出抗肿瘤作用。 | |||
T71169 |
XMD-12
|
Others | Others |
XMD-12, also known as DUN57447, Aurora inhibitor (compound 1) or Aurora-IN-1, is an Auroro inhibitor, which targets Aurora A/B/C. (5.6/18.4/24.6 nM). | |||
T70600 |
BRD-7880
|
Others | Others |
BRD-7880 is a potent and highly specific inhibitor of aurora kinases B and C. | |||
T62484 |
Aurora Kinases-IN-2
|
Others | Others |
Aurora Kinases-IN-2 (compound 12Aj) 是一种 Aurora 激酶的有效抑制剂 (Aurora kinases),能够作用于 Aurora A (IC50: 90 nM) 和 Aurora B (IC50: 152 nM)。Aurora Kinases-IN-2 能够调节细胞周期蛋白 B1 和 cdc2 ,将细胞周期阻滞在 G2/M 期。Aurora Kinases-IN-2 能够用于研究癌症。 | |||
T36801 |
Binucleine 2
|
Others | Others |
Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki = 0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division ... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T83459 |
11α-O-Tigloyl-12β-O-acetyltenacigenin B
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
11α-O-Tigloyl-12β-O-acetyltenacigenin B 是Tenacigenin B 的酯类衍生物,源自藤黄藤 (MTC)。该化合物具有调节Aurora-A活性,对淋巴瘤显示出潜在的抗肿瘤效果。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01413 |
H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi)
H-2K,OVA,MHC,H2-K1 |
Mouse | HEK293 Cells |
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its se... | |||
TMPK-01412 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi)
SARS-CoV-2 epitope,MHC |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. | |||
TMPK-01416 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,SARS-CoV-2 epitope |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. |